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A B S T R A C T
Bradykinin-potentiating peptides (BPPs) from the South American pit viper snake venom were the ﬁrst
natural inhibitors of the human angiotensin I-converting enzyme (ACE) described. The pioneer
characterization of the BPPs precursor from the snake venom glands by our group showed for the ﬁrst
time the presence of the C-type natriuretic peptide (CNP) in this same viper precursor protein. The
conﬁrmation of the BPP/CNP expression in snake brain regions correlated with neuroendocrine functions
stimulated us to pursue the physiological correlates of these vasoactive peptides in mammals. Notably,
several snake toxins were shown to have endogenous physiological correlates in mammals. In the
present work, we expressed in bacteria the BPPs domain of the snake venom gland precursor protein, and
this puriﬁed recombinant protein was used to raise speciﬁc polyclonal anti-BPPs antibodies. The
correspondent single protein band immune-recognized in adult rat brain cytosol was isolated by 2D-
SDS/PAGE and/or HPLC, before characterization by MS ﬁngerprint analysis, which identiﬁed this protein
as superoxide dismutase (SOD, EC 1.15.1.1), a classically known enzyme with antioxidant activity and
important roles in the blood pressure modulation. In silico analysis showed the exposition of the BPP-like
peptide sequences on the surface of the 3D structure of rat SOD. These peptides were chemically
synthesized to show the BPP-like biological activities in ex vivo and in vivo pharmacological bioassays.
Taken together, our data suggest that SOD protein have the potential to be a source for putative BPP-like
bioactive peptides, which once released may contribute to the blood pressure control in mammals.
 2015 Elsevier Inc. All rights reserved.
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Extreme low levels of blood pressure (BP) can determine an
insufﬁcient blood ﬂow for adequate nutrition of all tissues of an
organism body. On the other hand, chronic severe high BP can
overload the heart, accelerate the aging process of the arteries, and
increase the risk of stroke, and consequently the maintenance of
adequate BP is highly desirable [1]. BP is controlled by several
systems, including the central nervous system (CNS) mechanisms,
which control the cardiac chronotropy and inotropy, and also
vasomotion, mediated by autonomic nervous supplies to organs. In
special, the sympathetic outﬂow to microvasculature is a key
regulator of the vascular resistance, which is important to maintain
the BP levels [2,3].
The availability of reactive oxygen species (ROS) in neurons
located in brain areas involved in the control of sympathetic
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peripheral sympathetic tone and BP control in health and disease
[4–6]. The oxidative stress is the result of excessive generation of
oxidizing agents, and the inadequate removal of ROS and
consequent imbalance between the antioxidant and the pro-
oxidant mechanisms were shown to be involved in the pathogen-
esis of hypertension [7–9]. Any molecule presenting oxygen with a
high oxidative capacity is considered as potential ROS, as for
instance the superoxide ion (O2
), the hydroxyl radical (OH), and
the hydrogen peroxide (H2O2). The identiﬁcation of speciﬁc
activators and inhibitors of ROS is a challenge for a better
understanding of the underlying mechanism(s) of action involved
in the central BP control, besides having the potential value for the
development of new treatment strategies and representing today a
major target chosen by the pharmaceutical industry to develop
new drugs for several diseases [10].
Angiotensin II (Ang II) also controls vascular tone, growth and
apoptosis by multiple mechanisms, including the signaling
mediated by ROS [11,12]. Ang II has hypertensive activity by
promoting vasoconstriction [13] as well by acting on oxidative
stress [14,15]. Therefore, Ang II decapeptide antagonizes the
effects of the bradykinin (BK), which is a vasodilator peptide
[16]. Displaying contradictory actions, these humoral factors are
both crucial for the regulation of BP, and they are both modulated
by the action of the angiotensin I-converting enzyme (ACE), a key
enzyme for the renin–angiotensin system (RAS) [17]. The ﬁrst
reported natural inhibitors of ACE, coined as BK-potentiating
peptides (BPPs), were originally identiﬁed in the venom of a South
American pit viper [18,19]. They not only contributed to the
development of the ﬁrst site-directed inhibitor drug captopril used
in humans since a long time [18–22], as they were also essential for
the discovery of the humoral peptide BK [23], which is also know to
play roles in the CNS [24]. BPPs were therefore the inspiring
template and the perfect basis for the development of the
antihypertensive drug captopril, which may act primarily decreas-
ing the production of the hypertensive peptide Ang II and
decreasing the degradation of the hypotensive peptide BK [18–
21]. However, it is of worth mentioning that the effects of captopril
drug class on oxidative stress markers and antioxidant enzymes
have also been suggested more recently [25]. Moreover, it is also
well known that BK action through BK B2 receptor induces NO
release and upregulates the activity and expression of the
antioxidants Cu/Zn-SOD and Mn-SOD, with subsequent inhibition
of ROS production and suppression of the oxidative stress [26].
The cloning and sequence analysis of the cDNA encoding the
BPPs precursor from the venom gland of the South American pit
viper Bothrops jararaca (Bj) revealed that this precursor protein is
composed by seven tandem aligned BPPs forming a ‘rosary-type’
structure, followed by a C-type natriuretic peptide (CNP).
Natriuretic peptides (NPs) also play a fundamental role in the
cardiovascular homeostasis by modulating the ﬂuid and electro-
lyte balance, and the vascular tone [27]. Interestingly, the NPs were
also recently suggested to be the natural antagonists of the BK
receptor-signaling pathway, acting via regulation of G-protein
signaling proteins [28]. The expression of BPPs/CNP precursor in
snake tissues, besides the gland venom (namely spleen, pancreas
and brain) was demonstrated by our group in late 90s [29,30], and
this stimulated us to suggest that these peptides were endoge-
nously expressed by snakes, and that they could also be expressed
in mammals. In addition, the cloning and sequencing of the BPPs
precursor cDNA from Bj brain not only conﬁrmed the co-
expression of the CNP in the same precursor protein in the CNS
in the same was as in the venom gland, as well as in situ
hybridization studies showed the expression of BPPs/CNP precur-
sor in snake CNS regions associated to the regulation of
neuroendocrine functions [30]. In addition, we believe that therecent demonstration of the effects of snake BPPs on central BP
control of rats reinforces the hypothesis of the BPPs/CNP roles as
neuropeptide hormones [31–33].
Many isoforms of BPPs isolated from the venom glands of
several snakes, and also from other venomous animals such as
scorpions, and spiders, also have the ability to potentiate the
hypotensive effect of BK [34,35]. However, although unavoidably
displaying the canonical proline-rich domain and the pyro-Glu
residue at the C- and N-terminus extremities, respectively, not
necessarily all BPP-like peptides are effective BK-potentiator and/
or have the ability to decrease the BP or inhibit ACE activity in vitro
[34–37]. As some potential BPP-like precursor proteins from other
snakes [34,35] or identiﬁed based on primary structural similarity
searches in the human genome database did not necessarily show
BK-potentiating activity (data not shown).
In this work, we describe for the ﬁrst time the recombinant
expression of the BPPs domain of the snake venom gland precursor
protein in bacteria. This recombinant protein was characterized
and used to raise highly speciﬁc polyclonal antibody against the
BPPs (anti-BPPs). The anti-BPPs antiserum was able to recognize
both the natural and recombinant snake BPPs precursor protein, as
well as they were also capable to recognize a single protein band in
the homogenates of both snake venom gland and adult rat brain, as
demonstrated by Western blot (WB) assays. This cytosolic protein
from rat brain was immune-traced during the chromatography
puriﬁcation steps, and it was biochemically isolated and charac-
terized, allowing the identiﬁcation of a protein with well-known
key roles in the regulation of BP and ROS pathway. The possible
structural and/or functional relationships between the BPPs and
this rat brain cytosolic protein, led us to suggest this protein as a
potential precursor for endogenous BPP-like peptides in mammals,
as it will be discussed herein.
2. Materials and methods
2.1. Chemicals and drugs
HPLC grade acetonitrile (AcN), triﬂuoroacetic acid (TFA) and all
other chemical reagents were from Nacalai Tesque (Kyoto, Japan).
Bovine serum albumin (BSA), captopril and bradykinin (BK), as well
any other chemical not speciﬁed in the text, were purchased from
Sigma–Aldrich Chemical Co. (St. Louis, MI, USA) including the
amino acids and other reagents for N-9-ﬂuorenylmethoxycarbonyl
(Fmoc) chemistry. The skim milk used was MOLICO1 (Nestle´ Brasil
Ltda., SP, Brazil).
2.2. Animals
Genetically selected high antibody producer mice [HIII mice]
[38] were used for the production of the antibodies, and they were
maintained at the animal facilities of the Special Laboratory of
Microbiology of the Instituto Butantan (SP, Brazil). Male guinea pig
(180–200 g body weight) and male Wistar rats (250–280 g body
weight) were bred in animal care facility of the Instituto Butantan
(SP, Brazil). Male spontaneously hypertensive rats (SHRs) (250–
280 g body weight) were bred in animal care facility of the
Biological Science Institute, University of Sao Paulo (SP, Brazil). The
animals had free access to food and water and were submitted to a
light/dark cycle (12 h each) before the preparation for the
experiments. All animals were caged and handled under ethical
conditions according to international rules of animal care, stated
by the International Animal Welfare Recommendations [39], and
in accordance with the guidelines established by our local
institutional animal welfare committee (CEUAIB/Instituto Butan-
tan, protocol N8 443/2008).
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The recombinant bradykinin-potentiating peptide (BPP) was
expressed by subcloning into the expression vector pProEx-HT
(Invitrogen/Life Technology, Carlsbad, CA, USA) the BPP precursor
protein cDNA fragment coding for the domain containing the seven
BPPs. Escherichia coli BL21(DE3) strain was then transformed with
this expression vector and, after ampliﬁcation of this clone, the
expression was induced by the addition of 1 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) followed by incubation at 37 8C for
4 h with agitation at 200 rpm. The bacteria were recovered from
this culture by centrifugation and the bacteria pellet was frozen at
20 8C before sonication, recovery, and puriﬁcation of the
recombinant protein by afﬁnity chromatography with Ni-NTA
agarose (Qiagen, Hilden, Germany). The obtained sample was
analyzed by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS/PAGE) followed by Coomassie Blue and/or silver
staining or followed by Western blot (WB) analysis. To assure a
higher purity, the obtained recombinant protein was further
subjected to a preparative SDS/PAGE, and the protein band of
interest was then cutout and electro-eluted from the gel before the
primary sequence of the puriﬁed protein was conﬁrmed by MALDI-
TOF mass spectrometry (TofSpec-E, Micromass, Waters Corp.,
Milford, MA, USA).
2.4. Immunological assays
2.4.1. Production of speciﬁc antibodies
Twenty mg of recombinant BPP precursor protein emulsiﬁed
with Incomplete Freund’s Adjuvant (IFA) was given to each HIII
Balb/C mice divided into three batches of six 4-weeks old females.
In the ﬁrst batch, the emulsiﬁed sample was injected subcutane-
ously (SC). Subsequent boosters were given biweekly at the same
dose by intraperitoneal (IP) immunizations. The second batch was
initiated 44 days after the ﬁrst application of the ﬁrst batch. Only
5 of 6 mice received a dose SC, one of the mice was used as controls.
The following applications were performed every month by SC
injection.
Testing another immunization protocol, the third batch, was
immunized SC. For this batch, the following applications were
made every three months by SC injection. After every bled, the
sera were collected after centrifugation and stored at 20 8C
until use.
2.4.2. Determination of the antibody titers of antiserum
The recombinant BPP precursor protein was used as antigen for
the determination of the antibody titers of antiserum by enzyme-
linked immunosorbent assay (ELISA). Initially, 5 mg/mL of puriﬁed
recombinant BPP precursor protein was added to 96-wells plate
(Costar #3690, Corning, NY, USA), which was incubated at 4 8C
overnight for antigen ﬁxation. BSA was also used to increase the
ﬁxation on plate, and also served as negative control. Unbound
antigen was removed and the plate was incubated at 37 8C for 1 h
with the blocking solution (3% of skim milk in phosphate-buffered
saline – PBS). Then, the blocking solution was replaced with a serial
two-fold dilution of serum, starting at an appropriate dilution for
each serum. The pre-immune serum was also added in appropriate
dilution and used as control of binding. Wells were washed 6 times
with PBS to remove unbound antibodies, and a 1/5000 dilution of
alkaline phosphatase conjugated anti-mouse-IgG (H + L) (Pro-
mega, Madison, WI, USA) was used as secondary antibody. Then
the plate was incubated at 37 8C for 1 h with 1 mg/mL of
p-nitrophenylphosphate in 1.5 M NaCl and 0.1 mM Tris pH 9.8,
as substrate, for the color development. The reaction was stopped
by the addition of 2 mol/L NaOH, and the absorbance was read at
405 nm using a SpectraMax 1900 microplate reader (MolecularDevices Corporation, Sunnyvale, CA, USA). The antibody titers were
expressed as the log2 of maximum antiserum dilution giving an
absorbance twice as high as the absorbance of the control. The
control corresponds to addition of pre-immune serum instead of
antiserum dilution.
Immunoglobulin isotypes IgG1 and IgG2a were evaluated from
antisera of mice primed with carrier protein and unprimed mice.
For this purpose, 1:2000 dilution of alkaline phosphatase
conjugated rat anti-mouse-IgG1 or anti-mouse IgG2a (BD Bios-
ciences Pharmigen, San Diego, CA, USA) was used as secondary
antibody. Antibody titer was determined as described above.
2.4.3. Western blot of cytosol of rat tissues using the anti-BPPs
After electrophoresis on SDS/PAGE, samples were transferred
by electrophoresis onto a nitrocellulose membrane using transfer
buffer (25 mM Tris–HCl pH 8.3, 0.2 M glycine, 20% methanol),
under constant voltage of 30 V for 16 h. Membrane was then
blocked with a buffer containing 5% solution of BSA in TBST buffer
[150 mM NaCl, 20 mM Tris–HCl pH 7.5, and 0.05% Tween-20], for
1 h, followed by three washes with TBST. Membrane was
incubated with the primary antibody (anti-BPPs) diluted in TBST
for 1 h. After this period, the membrane was washed with TBST
solution three times for 10 min each, on shaker at room
temperature (25 8C). After washing, membrane was incubated
with the secondary antibody anti-mouse IgG conjugated with
alkaline phosphatase (Promega) diluted 1:7500 in TBST buffer for
1 h. After incubation, membrane was washed three times in TBST
buffer for 10 min each. Finally, the proteins bands were revealed
with a buffer containing 0.10 M Tris–HCl pH 9.5, 0.02 M NaCl,
0.005 M MgCl2 containing 5-bromo-4-chloro-3-indolyl phosphate
(BCIP) and nitro blue tetrazolium (NBT).
2.5. Preparation of rat brain cytosol proteins and separation by
chromatography
2.5.1. Preparation of cytosolic extract from rat tissues
Wistar rats were anesthetized, heparinized and subjected to
intracardiac perfusion with saline 0.9% NaCl. Brain tissue was
homogenized with 3 volumes (v/w) of buffer containing 0.1 M
Tris–HCl pH 7.5 and 0.25 M sucrose. The samples were then
centrifuged at 3000 rpm for 15 min at 4 8C. Each supernatant was
ultra-centrifuged tube at 100,000  g for 1 h at 4 8C. An aliquot of
the cytosol obtained was submitted to qualitative analysis through
electrophoresis in SDS/PAGE, and the remainder was freeze-dried
or concentrated in a speed-vac (Savant Instruments Inc., Holbrook,
NY, USA) and stored at 4 8C for later use.
2.5.2. Isolation of proteins from rat brain cytosol by gel ﬁltration
Cytosolic fraction of rat brain was obtained as described above.
An aliquot of 3.0 mL of this sample was applied to a column
chromatography Sephadex G-50 (3.5 cm  93.0 cm) in order to
obtain a separation of the fractions containing the proteins
recognized by anti-BPPs. Fractions were eluted with the buffer
0.2 M ammonium acetate pH 6.3. We collected 5 mL fractions and
absorbance reading at 280 nm was monitored in the spectropho-
tometer. The fractions containing protein were selected and
analyzed through SDS/PAGE and WB using anti-BPPs.
2.5.3. Isolation of rat brain proteins between 10 and 100 kDa
The chromatography fractions containing the protein of interest
(revealed by WB) were pooled. Each pool formed was concentrated
using ﬁltration system (CENTRICON, Amicon, Millipore Corpora-
tion, Billerica, MA, USA), primarily with 100 kDa membrane, and
then with 10 kDa membrane. Further analysis in SDS/PAGE and WB
were performed to verify the losses of target protein during the
ﬁltration process.
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2D SDS/PAGE or liquid chromatography
For 2D SDS/PAGE, the ﬁrst-dimension isoelectrophoresis was
performed in IPGphor (GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK) according to manufacturer’s using a using a pre-
cast immobilized pH 3–10 strip, and after the isoelectric focusing
(IEF), the samples were further resolved in a second dimension by
SDS/PAGE 12.5%, prepared in duplicate. After electrophoresis, one
gel was stained with Coomassie Blue while other was transferred
by electrophoresis onto a nitrocellulose membrane as described
above (Section 2.4.3). The protein spot of interest was then cutout
and digested overnight with trypsin for mass spectrometry (MS)
analysis.
High performance liquid chromatography (HPLC) was per-
formed using a Shimadzu (Shimadzu Corp., Kyoto, Japan) system
(model CBM-101), equipped with two pumps (model LC-10Advp),
Rheodyne injector (model 7725i) with loop injection of 100 mL,
UV-visible detector (model SPD 10AV) coupled with an analytical
C-18 column (Ultrasphere ODS, Beckman – 4.6 mm  250 mm/Ø
5 mm). The sample was resuspended in solvent A (0.1% TFA/H2O)
and loaded into the system. The fractions were eluted in a gradient
of 25–75%, solvent B (AcN/TFA 0.1%) over 30 min according to their
absorbance at 214 nm, under a constant ﬂow rate of 1 mL/min.
Each peak was independently collected and analyzed by one
dimension SDS/PAGE, prepared in duplicate. After electrophoresis,
one gel was stained with Coomassie Blue while other was
transferred by electrophoresis onto a nitrocellulose membrane
as described above (Section 2.4.3). The protein band of interest was
then cutout and digested overnight with trypsin for mass
spectrometry (MS) analysis.
2.6. Peptide synthesis
Peptides synthesis was performed on an automated PSSM-8
peptide synthesizer (Shimadzu Corp.), by a stepwise solid-phase
method, using N-9-ﬂuorenylmethoxycarbonyl (Fmoc) chemistry
[40]. Cleavage of the peptide from the resin was achieved by
treatment with a mixture of TFA/1,2-ethanedithiol/ethyl methyl
sulﬁde for 2 h at room temperature. The resin was removed by
ﬁltration and twice washing with TFA. The crude synthetic peptide
was puriﬁed by preparative reversed-phase HPLC (Shimadzu
Corp.) on YMC-Pack ODS column (20 mm  150 mm; YMC, Kyoto,
Japan), using a linear gradient from 3% to 20% AcN in 0.1% TFA, at a
ﬂow rate of 5 mL/min. Both the purity and primary structure of
each synthetic peptide were conﬁrmed by analytical HPLC and
MALDI-TOF mass spectrometry (TofSpec-E, Micromass, Waters
Corp., Milford, MA, USA). Samples were frozen in liquid nitrogen
and freeze dried for 48 h, at 50 8C, under vacuum (Edwards
Freeze Dryer Super Modulyo Pirani 1001, Thermo Fisher Scientiﬁc,
Waltham, MA).
2.7. Biological assays for synthetic peptides
2.7.1. Contractile effect on smooth muscles
Potentiating activity of the putative peptides of superoxide
dismutase (SOD) on the contractile effect of bradykinin (BK) on
smooth muscle was measured using preparations of isolated
guinea pig ileum. After 18–24 h fasting period, approximately
the distal ileum of guinea pigs was removed immediately
after death and washed thoroughly with Tyrode’s solution
(137 mM NaCl, 2.70 mM KCl, 1.36 mM CaCl2, 0.49 mM MgCl2,
0.36 mM NaH2PO4, 11.9 mM NaHCO3, 5.04 mM D-glucose). Cut
segments of 2.0 cm of the isolated ileum were mounted at
isotonic condition, under 1 g load, in 5 mL of muscle bath
containing Tyrode’s solution maintained at 37 8C and bubbled
with air.2.7.2. Systolic blood pressure (BP) recording in anaesthetized rats
BK-potentiation on systolic blood pressure (BP) recording in
anaesthetized rats assays were performed as previously described
[41]. Before the experiment, male Wistar rats (250–300 g) were
anesthetized with urethane 12% (1.0 mL/100 g weight body) IP,
and a polyethylene catheter (PE-10 connected to a PE-50) was
inserted into the abdominal aorta through the femoral artery for
arterial pressure measurements. For intravenous (IV) bolus
injections, polyethylene catheter was implanted into the femoral
vein. The cannulas were closed by a metallic pin and ﬁlled with
isotonic saline solution. Pulsatile arterial pressure (PAP), mean
arterial pressure (MAP) and heart rate (HR) were continuously
monitored by a solid-state strain gauge transducer connected to a
computer using a data acquisition system (MP 100; BIOPAC
Systems Inc., Santa Barbara, CA). The rats were kept anesthetized
during the experiments. After BP stabilization, the BK hypotensive
response on BP was standardized using doses of 0.5 and 1.0 mg. For
testing and comparisons of the effect of injection of the synthetic
peptides, different doses (30, 60 and 120 nmol) of SODa and
60 nmol of SODb peptide were injected in bolus, in each animal,
followed by 0.5 mg of BK injections in 5, 10, 15, 20, 25 and 30 min.
The number of animals (N) used for each peptide was: SODa
30 nmol (N = 6); SODa 60 nmol (N = 6); SODa 120 nmol (N = 5);
and SODb 60 nmol (N = 5). Peptides were dissolved in sterile
isotonic saline (0.9% NaCl) immediately before use. Statistical
comparisons were made using the effect of 0.5 mg of BK before the
drug injection as reference.
2.7.3. BP and heart rate (HR) recording in non-anaesthetized rats
SHR were anesthetized by IP injection of ketamine (150 mg/kg)
and xylazine (11.5 mg/kg) before stereotactic surgery, performed
to implant the cannula in the cerebral lateral ventricle (LV). The
animals recovered from the interventions for at least 4 days before
any measurements were recorded. One day before the experi-
ments, animals were anesthetized by IP injection of ketamine
(150 mg/kg) and xylazine (11.5 mg/kg) for the catheter implanta-
tion (Tygon Flexible Plastic Tubing – Saint-Gobain PPL Corp.) in the
femoral artery. The catheter was exteriorized and ﬁxed on the
upper back of the animal. One day after cannulation, the femoral
catheter was connected to a pressure transducer. The BP and HR
were recorded in non-anaesthetized animals with a Biopac System
(Biopac Systems Co.). Both mean BP (MAP) and mean HR (MHR)
were recorded continuously for 30 min after stabilization of BP.
The animals were divided into three groups, and on the ﬁrst day
after cannulation, the rats in group 1 received the injection, into
the LV, of SODa peptide (1.4 nmol/kg); in group 2 received SODb
peptide (1.4 nmol/kg) and, in group 3, the rats received injections
of the vehicle, and they were considered as a control group. BP and
HR were both monitored for 6 h, and the values were recorded at
every 15 min. After experiments, the rats were deeply anesthe-
tized, and submitted to vascular perfusion through the heart with a
10% buffered formalin solution, after injection of Evans blue (1 mL)
through the cerebral cannula. After sacriﬁce by decapitation, the
brains were removed, ﬁxed in 10% formalin and stored in 30%
sucrose solution. Transverse slices of the brain were prepared
(50 mm-thick) for the analysis and conﬁrmation of the presence
and distribution of the injected compounds in the lateral ventricle
(LV) by visual observation of the presence of Evans blue dye.
2.8. Structural analysis by bioinformatics
2.8.1. Rattus norvegicus SOD1 modeling procedures
Cu, Zn SOD (EC 1.15.1.1), also known as SOD1, from R. norvegicus
(UniProt ID: Q6LDS4_RAT) is a protein composed by 152 amino
acids. The SOD1 has no experimental three-dimensional (3D)
structure deﬁned and it was used in this work as a target in a
Fig. 1. Analysis of the speciﬁcity of anti-BPPs. (A) Sodium dodecyl sulfate–10%
polyacrylamide gel electrophoresis (SDS/PAGE). (B) Western blot (WB) analysis
using a pool of anti-BPPs serum and the secondary antibody anti-mouse IgG
conjugated with alkaline phosphatase. For (A) and (B): (1) recombinant BPP
precursor protein (5 mg), (2) cytosol of Bothrops jararaca brain (20 mg), (3) cytosol of
adult Wistar rat brain (50 mg) and (MW) protein size marker (in kDa).
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homologous proteins in the PDB database, and then Modeller 9 v.6
program [43] for protein modeling. The human Cu, Zn SOD (PDB
code: 1HL5) has 83% of amino acids identical and 89% of similarity
to rat SOD1, and therefore, its 3D structure was used here as the
template for homology modeling of rat SOD1. Then the obtained
3D model was evaluated by both Ramachandran plot analysis [44]
and ProSA-web program [45]. The model created was labeled here
as SOD1.
2.8.2. R. norvegicus SOD1 structural analysis
Structural analysis was initiated by studying the accessibility of
BPP-similar peptides named as SODa and SODb. For this purpose,
we used SurfV program [46] to calculate solvent accessibility area
per residue, which allowed us to analyze if SODa (residues 21–27)
and SODb (residues 54–61) regions are located at molecular
surface and exposed to a solvent above a selected threshold:
residues exposed above 25% of their total surface area. Addition-
ally, we used STING server [47] to generate the ‘‘TGZ’’ ﬁle
containing all STING structure descriptors. The TGZ ﬁle was used
as input to Java Protein Dossier [48], in order to analyze other
physical–chemical features of amino acids for a given 3D
conﬁguration. PyMol [49] was then used to generate the
molecular images.
2.8.3. Homologous sequences and cleavage sites analysis
In order to check the presence of the BPP-like peptides in SOD
proteins from other organisms, the primary sequences of R.
norvegicus SOD (SODC_RAT) homologous proteins were selected
using BLASTp [42] against SwissProt, and they were then aligned
using ClustalW 2.1 [50]. Primary sequences from mammals with
more than 70% identity and having similar regions to BPP-like
peptides, identiﬁed by BLASTp, were selected to be used in this
analysis. Therefore, the selected sequences for analysis were (with
SwissProt codes): SOD from the primates Cebus apella, capuchin
monkey (SODC_CEBAP), Callithrix jacchus, common marmoset
(SODC_CALJA), Macaca mulatta, Rhesus monkey (SODC_MACMU),
Hylobates lar, lar gibbon (SODC_HYLLA) and Homo sapiens, human
(SODC_HUMAN); the Gilres Oryctolagus cuniculus, rabbit (SOD-
C_RABIT), Cavia porcellus, domestic guinea pig (SODC_CAVPO), Mus
musculus, house mouse (SODC_MOUSE); and the carnivore Canis
lupus familiaris, dog (SODC_CANFA).
Additionally, aiming to identify known proteases that could
recognize and cleave peptide bonds neighboring the BPP-like
sequences, theoretical protease cleavage sites analysis was
performed using the program PeptideCutter [51], which contains
information about known cleavage target sites of several proteases
(including commercially available enzymes). This database has a
module of prediction cleavage sites into a query sequence. The
sequence used in this approach was SODC_RAT. Besides, the
database CutDB was used to predict the known cleavage sites of rat
proteases, as this bank includes the enzymes from rat and other
organisms. A search was conducted using R. norvegicus proteases,
which returned a set of 172 proteolytic events (cleavage sites
identiﬁed onto known proteins), and for M. musculus, a total of
402 events. The cut sites were also compared manually to
neighboring regions of BPP-like sequences of SOD protein
sequence.
2.9. Statistical analysis
Comparisons were made by one-way analysis of variance
(ANOVA) with Newman–Keuls post-test using GraphPad Prism
5.0 software (GraphPad Software Inc., San Diego, CA). Data are
expressed as mean  SEM. The criteria for statistical signiﬁcance
were set at p < 0.05.3. Results
3.1. Expression and characterization of the recombinant protein
The cDNA fragment coding for the precursor protein domain
containing the seven bradykinin-potentiating peptides (BPPs) was
subcloned in frame into the expression vector pProEx-HT
(Invitrogen) and allowed the expression of a predominant protein
band that migrated close to the region of 20 kDa, as observed by
denaturing polyacrylamide gel electrophoresis (SDS/PAGE) analy-
sis followed by Coomassie Blue and/or silver staining (Fig. 1A),
although the theoretical expected MW was estimated as
18,169.5 Da.
Mass spectrometry analysis of this afﬁnity puriﬁed protein
sample, before and after tripsinization, conﬁrmed that the
expressed recombinant protein corresponded to the expected
theoretical deduced amino acid sequence of the BPPs domain of the
snake precursor protein (Table 1).
3.2. Production of speciﬁc antibodies to BPPs by immunization with
recombinant protein
The antibodies against the BPPs (anti-BPPs) were raised by
three different immunization protocols. Three cohorts of Balb/c
immunized as described in Methods, using the obtained recombi-
nant protein (as described above), allowed raising antisera with
similar titers, regardless of the employed immunization protocol.
Essentially, the following protocols were evaluated here: fort-
nightly, monthly or quarterly immunizations (Fig. 2). The biweekly
immunization protocol yielded a larger volume of serum with
elevated titer in a shorter period. Despite requiring a longer period
for the obtainment of more speciﬁc sera against the BPPs, the
monthly or quarterly immunization protocols needed less amount
of the recombinant protein for the immunizations procedures, as
fewer booster injections were necessary in these later protocols.
We believe that the monthly or quarterly immunization protocols
may also determine a lower animal suffering, as they were less
manipulated along all immunization process, and that the ﬁnal
obtained antisera were qualitatively and quantitatively very
similar for the several immunizations frequencies evaluated here,
as demonstrated by WB and ELISA assays, with no signiﬁcant
differences in quality or speciﬁcity for the antibodies. However,
speciﬁcally the 8th and 9th bleedings of the fortnightly/biweekly
Table 1
Mascot search results for ESI-TRAP mass spectrometry analysis of trypsin digested samples.
Mascot search results for ESI-TRAP analysis of trypsin digested samples
Protein band Match to Seq coverage Score for each analysis No. of unique peptides No. of match queries



























Fig. 2. Production of anti-BPP by immunization of Balb/C mice with the
recombinant BPPs domain of the precursor protein. Mice were immunized with
20 mg of protein emulsiﬁed with IFA. Day 0 corresponds to the ﬁrst immunization,
and the bled was performed 3 days after each booster. Titers of batch of animals
immunized biweekly (square), monthly (diamond) and quarterly (triangle) on a
plate coated with recombinant BPP precursor protein-BSA. (B) The antibody titer
was determined comparing to the binding level of preimmune serum (log2).
Fig. 3. SDS/PAGE analysis for the fractions from the gel ﬁltration chromatography of adult
column and the eluted fraction were monitored at l = 260 nm, and the obtained fractions
each pool and total brain homogenate (6) were submitted to 12.5% SDS/PAGE followed b
BPP antiserum (B). The molecular weight standards (M) are indicated on the left for (A) an
recognized by the anti-BPPs antiserum.
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degree of cross-reactivity). These sera aliquots allowed detecting a
clear single protein band of about 17 and 16 kDa in the total cytosol
of snake and rat brain homogenate, respectively, in addition to a
very intense and speciﬁc recognition of the recombinant BPPs
domain precursor protein with theoretical expected MW estimat-
ed as 18,169.5 Da that migrated close to the region of about 20 kDa
(Fig. 1B), even after long exposition periods. Therefore, these serum
aliquots were chosen for use in the following steps of this work.
3.3. Isolation and puriﬁcation of the BPPs immune-related protein
from the rat brain cytosol
Considering that the immune-recognized protein from the
adult rat brain has a MW of about 16 kDa, as demonstrated by WB
analysis (Fig. 1B), the total proteins from a whole cytosol
homogenate of adult rat brains were initially fractionated by gel
ﬁltration using a Sephadex G-50 resin, and all obtained fractions
were analyzed by SDS/PAGE and WB, allowing the identiﬁcation of
the fractions that contain the proteins immuno-recognized by the
anti-BPPs serum, which at this step were basically two bands of
about 16 and 32 kDa (Fig. 3).
The chromatography fractions containing the protein(s) of
interest, as determined by WB, were then pooled and size sorted
using microcentrifuge columns with cut-off for 100 kDa, which rat brain cytosolic homogenate. The homogenate was applied into a Sephadex G-50
 were pooled as 16–30 (1), 31–40 (2), 41–50 (3), 51–58 (4), and 59–90 (5). Aliquots of
y staining with Coomassie brilliant Blue (A) or Western blot analysis using the anti-
d (B), and the arrow in panel (B) indicate the protein band of about 17 kDa, immune-
Fig. 4. 2D SDS/PAGE of the fraction containing the immune-recognized protein of interest. First-dimension isoelectrophoresis was performed in IPGphor (GE Healthcare)
according to manufacturer’s using a using a pre-cast immobilized pH 3–10 strip, and after the isoelectric focusing (IEF), the samples were further resolved in a second
dimension by SDS/12.5% PAGE, prepared in duplicate. One gel was stained with Coomassie brilliant Blue (A) and the other was analyzed by Western blot using the anti-BPP
antiserum (B) The collected protein spot is indicated by the arrow.
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100 kDa). And then, the low molecular weight fraction of the
sample containing the protein of interest was concentrated by
ﬁltration in Centricon columns with cut-off for 10 kDa.
For further isolation and biochemical characterization/identiﬁ-
cation of the immune-recognized protein, two-dimensional
electrophoresis in polyacrylamide gel (2D/PAGE) and high perfor-
mance liquid chromatography (HPLC) fractionation were
employed. The 2D/PAGE analysis followed by Coomassie Blue
and/or silver staining allowed to observe the total protein
composition of the concentrated low molecular weight fraction
sample (Fig. 4), and WB analysis conﬁrmed the presence of
16 kDa protein recognized by the anti-BPPs antibody (Fig. 4). The
immune-recognized spots were then cutout from the 2D/PAGE gels
stained with Coomassie Blue, and the sample was trypsinized
before the mass spectrometry (MS) ﬁngerprint analysis.
Aiming a more reﬁned isolation and to conﬁrm the 2D/PAGE
results, the same concentrated low molecular weight fraction
sample containing the protein of interest was also fractionated by
HPLC, and the observed peaks were individually collected and once
more analyzed by SDS/PAGE and WB using the anti-BPPs
antiserum. A single protein band of about 16 kDa was observed
only in the fraction eluted at 16 min (data not shown), and this
immunorecognized protein band was excised from the Coomassie
Blue stained one dimension SDS/PAGE, before trypsinization and
MS ﬁngerprint analysis.
The identiﬁcation by MS of these proteins (of about 16 and
32 kDa), isolated by either 2D/PAGE or HPLC, consistently
conﬁrmed that the immune-recognized rat brain proteins are in
fact the endogenous antioxidant enzyme Cu, Zn superoxide
dismutase (SOD), which plays a key role in the blood pressure
(BP) regulation and has a molecular weight of 15,871 Da and
isoelectric point of 5.88. The about 32 kDa protein was shown to
correspond to dimers of the SOD (Table 1).
3.4. Homologous sequences and cleavage sites analysis
The selected sequences of mammalian SOD sequences were
aligned using ClustalW in order to highlight the conservation of
BPP-like regions within distinct groups of several animals. The
alignment is presented in Fig. 5A, and SODa and SODb peptides are
colored in blue and green, respectively. The identiﬁers of the SOD
protein sequences are colored accordingly to the taxonomic
group of the organism source: yellow for order Primates, red for
group Gilres and gray for order Carnivora. The ﬁrst BPP-like peptide[rat: QKASGEP] had the Gln21, Lys22 and Pro27 fully conserved. The
primates group have identical region in the SOD sequence and a
particular feature is observed: the presence of a glutamic acid at
the corresponding position of the rat Ala23 and a Gly residue in the
correspondent position of rat Glu26. This means that there is a
change of a non-polar to a charged residue in the ﬁrst site, and the
reverse situation in the second site, which might conserve the
electrostatic potential of the region. Additionally, in rat sequence,
this region is identical in mouse, and there is a loss of the charged
residue at BPP-like regions in the SOD from rabbit, guinea pig, and
dog. The second BPP-like region, comprising the SODb sequence is
more conserved, and all residues (unique exception for the
conservative change between Thr58 for a Ser) are present in the
SOD sequences from all analyzed animals. The human SOD
sequence has an Ala residue at the ﬁrst position of SODb region,
but all remaining SODb sequence is identical to that found in rat
SOD protein.
The program PeptideCutter was used here to search for
known protease cleavage sites neighboring the BPP-like regions.
The enzyme Asp-N endopeptidase + N-terminal Glu was sug-
gested to be able to cleave the F19–E20 bond preceding the BPP-
like SODa peptide and glutamyl endopeptidase could potentially
cleave the E20 peptide bond. Other enzyme with potential
interest is the thermolysin, which would be able to cut and
release the exact sequence of BPP-like SODa peptide, acting at
positions 20 and 29 of rat SOD protein. Unfortunately, these
enzymes are originally from bacteria and obviously nobody
would expect these enzymes could be the responsible for the
cleavage and processing of a mammal cytosolic SOD, except if
other enzyme with similar catalytic speciﬁcity of thermolysin
exists in the cell cytosol providing the appropriate scenario for
this endogenous cleavage. Thus, the database CutDB was used to
search for cut sites of known rat and mouse proteases. After a
manual check, it was possible to notice that ADAM10 peptidase
may be able to recognize and cleave a similar sequence to that
found at BPP-like peptides C-terminal region. The cleavage site
of ADAM10 at p75 neurotrophin receptor is SSQP-VVT, which is
similar to the region found at SOD (i.e. SGEP-VVV). Interestingly
it is discussed that the active sites of ADAM10 peptidase and
thermolysins may be similar to each other [52]. No obvious
cleavage sites similar to the regions neighboring the BPP-like
sequences of SODa could be found in rat database. On the other
hand, in mouse database, a cleavage site between a glutamate
and a glutamine residue (similar to E20–Q21 site found in SOD)
is described in the Trim28 transcription intermediary factor
Fig. 5. Sequence alignment of mammalian SODs and 3D structure of modeled rat SOD1. (A) Primary sequence alignment of mammalian SODs by ClustalW. The codes are
displayed with NCBI identiﬁer (gi) and SwissProt identiﬁcation from organisms deﬁned in materials and methods. (B) Rattus norvegicus 3D structure of modeled SOD1. The
BPP-like peptides SODa and SODb are highlighted in blue and green, respectively, showing that they are exposed to a solvent, located at the molecular surface. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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unknown protease [53]. It is clear that it is not possible for us to
suggest here that these enzymes are involved in the cleavage and
processing of the SOD protein, but the conceivable existence of
enzymes that can potentially cleave proteins in similar
recognition sites, as the one neighboring the BPP-like peptides
found in rat SOD protein, may support the hypothesis of a
possible existence of endogenous proteases with ability to
cleave SOD and to release the active BPP-like peptides.
Experimental works are still required to conﬁrm this hypothesis,
but the chemical synthesis of the expected mature BPP-like
peptides may also be an important step to ﬁrst conﬁrm the
potential pharmacological effects of these peptides, once
released from the precursor protein.3.5. R. norvegicus SOD1 modeling
The modeled SOD1 structure was evaluated by Ramachandran
plot analysis and validated as good because 147 residues (98% of
residues) are located at most favored regions. ProSA web service
conﬁrmed the high quality of model having a compatible z-score
(7), located within the range of scores typically found for native
proteins of similar size. ProSA also showed a good local model
quality since the average energies (for 40 and 10 residues window
size) are predominantly negative.
Then, we used SOD1 coordinate ﬁle to perform SurfV
calculation. The output was used to analyze whether BPP-similar
regions containing the ‘‘SODa’’ and ‘‘SODb’’ peptides are located at
surface and if they are exposed to the solvent above the threshold
Table 2
Accessible area and percentage of exposure to a solvent for BPP-similar peptide of
rat SOD1 peptide SODa and SODb.
BPP-like peptides from modeled rat SOD1
Position Amino acid Accessibility % of total amino
acid area at surface
SODa 21 Q 20.08 6.27%
22 K 178.30 49.78%
23 A 56.56 23.67%
24 S 104.35 41.72%
25 G 61.21 29.20%
26 E 45.69 13.68%
27 P 38.90 14.46%
Average 72.16 25.54%
SODb 54 Q 121.53 37.95%
55 G 32.25 15.39%
56 C 20.53 7.60%
57 T 94.00 33.58%
58 T 36.36 12.99%
59 A 0.00 0.00%
60 G 14.72 7.02%
61 P 86.50 32.14%
Average 50.74 18.33%
Table 3
EC50 values for captopril (control) and rat SOD1 derived putative peptides
(namely SODa and SODb). Potentiating activity of the putative peptides of
SOD on the contractile effect of BK on isolated guinea pig ileum using
captopril as positive control. The number of experiments (N) and the
standard error of the mean (S.E.M.) are presented.
Drug EC50 (nM)
BK (N = 10) 1.93  0.40
BK + captopril 15 nM (N = 10) 0.20  0.15*
BK + captopril 45 nM (N = 10) 0.34  0.10*
BK + captopril 150 nM (N = 10) 0.33  0.06*
BK (N = 10) 1.78  0.38
BK + SODa 45 nM (N = 6) 1.45  0.47
BK + SODa 150 nM (N = 10) 1.19  0.25
BK + SODa 450 nM (N = 10) 1.09  0.22
BK + SODa 1500 nM (N = 4) 1.18  0.30
BK (N = 10) 2.59  0.43
BK + SODb 45 nM (N = 6) 2.04  0.45
BK + SODb 150 nM (N = 10) 1.91  0.33
BK + SODb 450 nM (N = 10) 1.37  0.33
BK + SODb 1500 nM (N = 4) 3.12  0.83
* p < 0.05.
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showed that SODa peptide [QKASGEP], located at position 21–27 of
rat SOD1, is exposed to a solvent with an average of accessible area
per residue of 72.16 A˚2 (25.54% of respective total surface area), as
is shown in Table 2. These residues are located on a loop between
two anti-parallel b-strains (Fig. 5B). The most exposed residues are
those polar: e.g. Lys22 and Ser24 (178.30 A˚2 and 104.35 A˚2 of
accessible area, respectively).
The BPP-like peptide SODb [pQGCTTAGP] located at position
54–61 of rat SOD1 was also evaluated with respect to solvent
exposure, and we found that although also exposed, it is less
exposed than the SODa peptide. There, an average of 50.74 A˚2 of
accessible area was found (18.33% of respective total surface area),
as is shown in Table 2. These residues are located in a loop with
polar Gln54 and Thr57 (121.53 A˚2 and 94.00 A˚2 of accessible area,
respectively), as most exposed amino acids. It is important to
emphasize that the Cys56 (of the SODb peptide) is establishing a
disulﬁde bridge with Cys145, what approximates the SODb region
to protein core and creates a small a-helix like conformation,
which hides Ala59 (which is not exposed). Modeling and 3D
structure analysis also demonstrated the high exposure of these
peptides in SOD1 protein surface as follows (Fig. 5B).
3.6. Synthesis of SOD peptides
As mentioned, the SOD enzyme is an endogenous antioxidant
with a key role in regulating BP, which is in line with the activities
described up to now for the BPPs [35]. However, a comparison of
SOD primary sequence to the BPPs precursor protein showed little
or no primary sequence similarity (data now shown). On the other
hand, knowing that the BPPs are typically composed by 5–17
amino acid residues per molecule, with an invariable pyroglutamic
acid (after post-translational modiﬁcation of the glutamine residue
at N-terminus of the peptide [29,30]) and a proline residues at the
N- and C-terminal extremities, respectively [54,55], two peptide
sequences presenting these features were identiﬁed in the rat
SOD1 primary amino acid sequence (Fig. 5). These peptides were
synthesized and named as SODa [pQKASGEP] and SODb
[pQGCTTAGP]. In other words, these peptide fragments of the
rat SOD sequence were chosen due to the presence of the
glutamine and proline residues spaced by less than 7 amino acid
residues, and also due the presence of arginine and/or tryptophan
residues, often observed in many BPPs isolated from snakes and
other animals [35]. Moreover, aiming to better mimic the nativeBPPs found in snake venom glands these SOD peptide fragments
were also synthesized with a pyro-Glu [pQ] residue at their N-
terminus.
3.7. Pharmacological assays with the SOD-derived synthetic peptides
To determine if the SODa [pQKASGEP] and SODb [pQGCTTAGP]
peptides synthesized based on the sequence of rat SOD1 have the
same pharmacological functional characteristics described for the
BPPs, their ability to potentiate the contractile effect of BK on
smooth muscle was evaluated using preparations of isolated
guinea pig ileum. Under the conditions tested in this assay, no
potentiation of BK activity in isolated smooth muscle was observed
for the peptides studied here (Table 3).
3.8. Systolic blood pressure recording in anaesthetized rats
The activity after peripheral injection of synthetic SODa
[pQKASGEP] and SODb [pQGCTTAGP] peptides on the BP of
anesthetized rats was also evaluated.
As observed, although the statistical analysis showed no
signiﬁcant BK-potentiating effect in the presence of low doses of
SOD peptides, it was possible to observe for SODa a trend to
potentiate the hypotensive effects of BK compared to the control.
This difference was not signiﬁcant as determined by the variation
in the maximum peak response for each animal, but it is important
to note that, for each animal, the maximum response was observed
at different time lapses, i.e. at 5, 10, 15, 20, 25 or 30 min after
peptide IV bolus injection (Fig. 6A and B). On the other hand, if the
maximum response was considered regardless of the response
time lapse, a clear signiﬁcant increase of the hypotensive effects of
BK compared to the control could be noticed only for the SODa
peptide with a dose–concentration response (Table 4 and Fig. 6C–F).
However, in contrast to the SODa peptide (Table 4 and Fig. 6C–F) and
the ACE inhibitory activity described for the snake BPPs [56], for
concentrations up to 120 nmol, the SODb peptide showed no
obvious ACE inhibition, evaluated by in vivo potentiation of the BK
hypotensive effects in anaesthetized rats (data now shown).
3.9. Blood pressure (BP) and heart rate (HR) recording in
unanesthetized spontaneously hypertensive rats (SHRs)
Taking into account that these BPP-like peptides were isolated
from the adult rat brain, we decided to evaluate whether the SODa
Fig. 6. Hypotensive effect of intravenous bolus injections of BK before and after SOD peptides administration in the blood pressure of anesthetized Wistar rats. (A) SODa,
60 nmol (N = 6), (B) SODb, 60 nmol (N = 6). (C) Average of maximal response on blood pressure in the anesthetized Wistar rats evoked by intravenous bolus injections of BK
before and after different doses of SODa, namely (D) SODa, 30 nmol (N = 6), (E) SODa, 60 nmol (N = 6) and (F) SODa 120 nmol (N = 5). Results extracted of each experiment
independent of time record (until 30 min after SODa injection). Data are expressed as mean  SEM. ***p < 0.001 SODa doses in comparison of the values obtained with 0.5 mg of
BK before SODa injection and ##p < 0.01 comparison between SODa doses 60 nmol vs. 30 nmol and 120 nmol vs. 30 nmol. (D–F) Data are expressed as mean  SEM. **p < 0.01 and
***p < 0.001 in comparison to the values obtained with 0.5 mg of BK before SODa injection.
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as described for the snake BPPs in CNS, after intraventricular (ICV)
brain injections in spontaneously hypertensive rats (SHRs) [36,57],
for which an increased baroreﬂex sensitivity and decreased mean
arterial pressure (MAP) and heart rate (HR) were described [32,33].
The ICV injection of SODa and SODb (Fig. 7) produced a
maximum hypotensive effect (DMAP) of about 28  4 and
23  3 mmHg, respectively, which are both more intense than that
observed for the control (12  2 mmHg) and also described for BPP-
5a (i.e. DMAP: 38  4 mmHg) [57]. The maximum delta heart rate
(DHR) for SODb (112  13 bpm) were also more intense than the
control (50  4 bpm) and also BPP-5a (DHR: 71  17 bpm) values
[57], although for SODa (86  17 bpm) only a trend to a smaller HR
was observed, as this difference was not statically different
(p = 0.0622).
In other words, the bradycardia was more intense and longer
than that observed for BPP-5a [57], with a maximum delta HR (of
about-197 bpm) achieved from 1 to 2 h after injection of SODa orTable 4
Percentage of maximal potentiation of BK hypotensive effect on rat blood pressure
after intravenous bolus injection of SODa peptide. Results extracted of each
experiment independent of time record (until 30 min after SODa injection). Data are
expressed as mean  S.E.M.
SODa dose (nmol) N Maximal potentiation (%)
30 6 24.9  4.5
60 6 46.2  13.5
120 5 65.6  11.8
N is the number of animals used for each peptide.SODb. In turn, SODb injection produced a maximum hypotensive
effect less intense than SODa, but that remained for longer
(monitored up to 360 min) compared to the fast decrease of the
MAP in the ﬁrst hour after injection of the peptide SODa followed
by a gradual recovery of the BP (data now shown). These effects
could be attributed to a reduction in the peripheral sympathetic
activity, and further studies are being conducted by the group to
clarify the eventual neural mechanism underlying the central
effects of these peptides.
Taken together, this assay allowed us to observe a decrease in
MAP, for SODa and SODb, both accompanied by a signiﬁcant
decrease in HR, but with a faster effect for SODa compared with
SODb, which showed a slower and long lasting effect. In other
words, the maximum hypotensive and bradycardic effects of SODa
and SODb were more severe and remained for longer than for BPP-
5a (Fig. 7).
4. Discussion
Efforts to search for bradykinin-potentiating peptides-like
(BPP-like) sequences in available databanks, by employing
different bioinformatics tools, were very frustrating, leading us
to identify couple of sequences from mammals with BPP-like
structure based on the primary structure and/or amino acid
composition, but with no effective in vitro and in vivo pharmaco-
logical effects for the respective identiﬁed peptide. Taking into
account that the 3D structure should be conserved for the
maintenance of the biological functions, we have concentrated
our efforts on strategies that allow the search for topologically
Fig. 7. Cardiovascular parameters changes in response to the ICV injection of SODa
and SODb into unanesthetized SHRs brain. (A) Delta mean arterial pressure (DMAP),
and (B) delta heart rate (DHR) compared to initial values, i.e. mean BP (MAP) and
mean HR (MHR) recorded continuously for 30 min after stabilization of BP, before
the ICV injection into the lateral ventricle (LV) of 1.4 nmol/kg of SODa (N = 7) and
1.4 nmol/kg SODb (N = 7). *p < 0.005 in comparison to the control. (C) Exemplary
transverse slices of the rat brain prepared (50 mm-thick) for the analysis and
conﬁrmation of the presence and distribution of the injected compounds in the LV
by visual observation of the presence of Evans blue dye.
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classically employed [58,59], although the high content of proline
residues characteristic of the snake bradykinin-potentiating
peptides (BPPs) may represent the principal limitation for this
approach due to the risk of eventual immune cross-reactivity. In
fact, previous attempts to raise speciﬁc antibodies against snake
BPPs demonstrated the challenging limitations imposed by using
short proline-rich peptides (PRPs) as antigen [60]. The employ-
ment of several innovative strategies culminated in the production
of anti-BPPs antiserum able to recognize a single band correspond-
ing to the BPP precursor protein in the cytosol of the B. jararaca
venom gland [56], but which was not able to speciﬁcally recognize
proteins in any other snake or rat tissue homogenates (data not
shown). In the present work, we demonstrate the high speciﬁcity
of anti-BPPs antiserum raised in mice by several immunization
protocols using puriﬁed recombinant BPP precursor protein
expressed in bacteria, which was shown to be able to recognize
a single protein band in the whole cytosol of snake and rat brain,
independent of the immunization protocol used. The antiserum
aliquot presenting the highest speciﬁcity against the adult rat brainhomogenate was used for the screening and tracking an immune-
recognized protein during the protein isolation process by
chromatography.
The fractionation of rat brains proteins using Sephadex G-50
chromatography column followed by size cut-off ﬁltration system
(Centricon) enabled the subsequent enrichment of the immune-
recognized protein in selected fractions (e.g. containing the protein
of interest), which underwent a ﬁnal isolation processes using
either two-dimensional denaturing polyacrylamide gel electro-
phoresis (2D SDS/PAGE) or high performance liquid chromatogra-
phy (HPLC). Our results revealed that these both methods were
effective in generating samples of the protein of interest with
enough amount and purity for further characterization steps. Mass
spectrometry (MS) ﬁngerprint analysis identiﬁed the 16 kDa
protein band as the Cu, Zn superoxide dismutase (SOD), which is an
enzyme classiﬁed as an endogenous antioxidant with a key role in
regulating blood pressure (BP). SOD has molecular weight of
15,871 Da and isoelectric point equivalent to 5.88 [61]. MS analysis
also allowed the characterization of the 32 kDa band, also
recognized by the anti-BPP antiserum in the rat brain cytosol, as
dimers of SOD. In fact, the trend of SOD to form dimers in high
concentrations is well known as was already described in the
literature [62].
Analysis of the primary sequence of rat SOD allowed the
identiﬁcation of two peptide sequences with glutamine and
proline residues spaced by less than 7 amino acid residues, and
also detected the presence of arginine and/or tryptophan residues,
often observed in many BPPs isolated from snakes and other
animals [35,54]. The modeling and 3D structure analysis of rat SOD
demonstrated the high exposure of these peptides, named as SODa
[pQKASGEP] and SODb [pQGCTTAGP], in the protein surface.
Modeled rat SOD1 structure was evaluated by Ramachandran plot
analysis and that was validated as good, as 147 residues (98% of
residues) are located at most favored regions. ProSA web service
also conﬁrmed the high quality of this model. The program
PeptideCutter allowed searching for known protease cleavage sites
neighboring the BPP-like regions, and the enzyme Asp-N
endopeptidase + N-terminal Glu was suggested to cleave the
F19–E20 bond preceding the BPP-like SODa peptide sequence,
and glutamylendopeptidase would be able to cleave the E20
peptide bond. Another interesting enzyme identiﬁed was thermo-
lysin, which would be able to cut the ﬂanking regions of the BPP-
like SODa peptide, cleaving at positions 20 and 29, suggesting the
existence of proteases with potential to cleave rat SOD and to
release the identiﬁed peptides. However, we are conscious that
experimental works are still required to conﬁrm this hypothesis, as
our efforts to identify these peptides by MS analysis of the low
molecular fraction of adult rat whole brains under physiological
conditions were unfruitful up to now.
Preliminary tests performed in anaesthetized rats with these
two peptides (SODa and SODb) synthesized with a pyro-Glu [pQ]
residue at the N-terminus, based on excerpts from the rat SOD
sequence, indicated that these BPP-like peptides have bradykinin
(BK) potentiating activity in vivo (Figs. 6 and 7), although ex vivo
assays using isolated guinea pig ileum did not show any
potentiating activity (Table 3). The difference in results obtained
in ex vivo and in vivo assays suggests that these synthetic peptides
may be able to potentiate the effect of BK, but not in isolated tissues
experiments (Table 3 and Figs. 6 and 7). This might suggest that the
mechanism of action of these putative peptides of SOD requires
pathways or effectors not available in isolated guinea pig tissues, as
it was demonstrated also for other BPPs from snake venom [35]. It
is well know that the BK action is dependent of its binding and
activation of the BK B2 receptor, which triggers intracellular
signaling through G-protein activation and consequent increase in
the SOD expression [63,26], which could be then the source for an
J.D.A. Campeiro et al. / Biochemical Pharmacology 96 (2015) 202–215 213increased release of these putative peptides. This suggestion is in
line with the recent scientiﬁc discovery trend suggesting the
importance of the production of bioactive peptides derived from
recycling and/or metabolism of proteins after their primary
function [64].
However, it is important to consider that the SOD was identiﬁed
in the brain cytosol and one would expect to see the effect of these
putative peptides in the central nervous system (CNS), taking into
account its hypothetical existence in the free form in the brain.
Interestingly, infusion of these synthetic SOD peptides into
spontaneously hypertensive rats (SHRs) brain showed bradycardic
and hypotensive effects in these animals, in similar fashion as
already described for several BPPs isolated from snakes [65],
suggesting a potential physiological central role for these peptides
in rodents and mammals. A signiﬁcant decrease in mean arterial
pressure (MAP) accompanied by a signiﬁcant decrease in heart rate
(HR) was observed for both SODa and SODb, in a similar way as
recently described also for the snake BPPs [31,32,36,57,65], but
with a slower and long lasting effect for SODb compared to the
faster effect of SODa (data not shown). Considering that the rat SOD
enzyme has a key role in regulating the BP, acting as an
endogenous antioxidant [66], it would be expected that peptide
fragments derived from SOD protein sequence could be biologi-
cally effective only in conditions suitable for the antioxidant
system’s triggering. It is well-known that SOD, as an antioxidant,
acts in the CNS by reducing the levels of reactive oxygen species
(ROS), which in turn increases the excitability of sympathetic
premotor neurons, subsequently reducing the sympathetic tone
[67], although vagal-mediated increase in parasympathetic tone
could not be ruled out [68,69,67,70], as angiotensin-converting
enzyme (ACE) inhibitors can signiﬁcantly increase vagal tone
[67,70]. Therefore, it would be conceivable that after this primary
action, SOD could also be the source of bioactive peptides that
could further decrease the BP by a mechanism of action that still
need to be unraveled. Although the potential involvement of NO
synthesis and Ca2+ inﬂux should also be considered for BPP-like
peptides [31–33,57].
Unfortunately, as mentioned, attempts to isolate these peptides
from adult rat brains under physiological conditions were
unsuccessful up to now. However we need to consider that it is
possible that these peptides can be found in very low levels/
concentrations or even be completely absent in physiological
conditions. So forth, pharmacological manipulations that could
potentially favor the release of these peptides are under study now.
The identiﬁcation of potential proteases with ability to release
these peptides from the SOD sequence, as those suggested by
bioinformatics analysis performed here, may open new insights for
novel experimental strategies to solve this question, not only for
rat brain protein, but also for the snake venom gland precursor
protein, as the BPPs production mechanism and bioactive peptide
release process still remain unknown.
Moreover, it is of note that despite the recognized and
overestimated importance of the canonical PIPP sequence in the
C-terminus of the snake BPPs for their biological activity on
potentiating the BK effects in isolated smooth muscles [34,35], the
recent ﬁnd of the group showed that the N-terminal variable
region plays a more decisive role for the in vivo effects of BPPs in
the BP, and a dissociation of antihypertensive and bradycardic
effects of snake BPPs [65]. Interestingly, among the various
biological functions endowed by PRPs present in many tissues and
biological ﬂuids of humans, we highlight the antioxidant proper-
ties and the potential therapeutic role of PRPs as a promising
source of new peptide based novel drugs [71].
The demonstrated signiﬁcant degree of ligand–receptor coevo-
lution with the evolution of peptidergic signaling should also be
considered here as this partnership may contribute in ﬁne tuningorchestrated multi-organ physiological outcomes, and conse-
quently, this may be subjected to selection pressures in the
evolutionary process supporting eventual pleiotropic interactions
among closely related ligands [72] as the BPP-like or PRPs family,
which are composed by a wide variety of structurally related
members [34,35,37].
The identiﬁcation of these peptides in their free form from CNS
preparations is under consideration for the continuation of the
present research project.
Acknowledgments
We are greatly thankful to Dr. Katsuhiro Konno for the initial
peptide synthesis used in this work and for the MS analysis. The
technical assistance by Maria Aparecida Siqueira is also greatly
recognized here. This study was supported by grants from FAPESP
(Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo), Conselho
Nacional de Desenvolvimento Cientı´ﬁco e Tecnolo´gico (CNPq), and
Coordenac¸a˜o de Aperfeic¸oamento de Nı´vel Superior (CAPES).
References
[1] A.H. Gradman, J.T. Wilson, Hypertension and diastolic heart failure, Curr.
Cardiol. Rep. 11 (6) (2009) 422–429.
[2] E. Colombari, M.A. Sato, S.L. Cravo, C.T. Bergamaschi, R.R. Campos Jr., O.U.
Lopes, Role of the medulla oblongata in hypertension, Hypertension 38 (3 (Pt
2)) (2001) 549–554.
[3] J.P. Fisher, J.F. Paton, The sympathetic nervous system and blood pressure in
humans: implications for hypertension, J. Hum. Hypertens. 26 (8) (2012)
463–475.
[4] Y. Kimura, Y. Hirooka, Y. Sagara, K. Ito, T. Kishi, H. Shimokawa, A. Takeshita, K.
Sunagawa, Overexpression of inducible nitric oxide synthase in rostral
ventrolateral medulla causes hypertension and sympathoexcitation via an
increase in oxidative stress, Circ. Res. 96 (2) (2005) 252–260.
[5] L. Gao, W. Wang, Y.L. Li, H.D. Schultz, D. Liu, K.G. Cornish, I.H. Zucker,
Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin
II and NAD(P)H oxidase, Circ. Res. 95 (9) (2004) 937–944.
[6] Y. Hirooka, Role of reactive oxygen species in brainstem in neural mechanisms
of hypertension, Auton. Neurosci. 142 (1–2) (2008) 20–24.
[7] M.C. Zimmerman, E. Lazartigues, R.V. Sharma, R.L. Davisson, Hypertension
caused by angiotensin II infusion involves increased superoxide production in
the central nervous system, Circ. Res. 95 (2) (2004) 210–216.
[8] T.M. Paravicini, R.M. Touyz, Redox signaling in hypertension, Cardiovasc. Res.
71 (2) (2006) 247–258.
[9] M.F. Giusti, M.A. Sato, L.M. Cardoso, V.A. Braga, E. Colombari, Central
antioxidant therapy inhibits parasympathetic baroreﬂex control in conscious
rats, Neurosci. Lett. 489 (2) (2011) 115–118.
[10] Q. Ma, Advances in mechanisms of anti-oxidation, Discov. Med. 17 (93) (2014)
121–130.
[11] R.M. Touyz, Intracellular mechanisms involved in vascular remodeling of
resistance arteries in hypertension: role of angiotensin II, Exp. Physiol. 90 (4)
(2005) 449–455.
[12] F. Tabet, E.L. Schiffrin, G.E. Callera, Y. He, G. Yao, A. Ostman, K. Kappert, N.K.
Tonks, R.M. Touyz, Redox-sensitive signaling by angiotensin II involves
oxidative inactivation and blunted phosphorylation of protein tyrosine
phosphatase SHP-2 in vascular smooth muscle cells from SHR, Circ. Res. 103
(2) (2008) 149–158.
[13] E.F. Carney, Hypertension: new non-RAS peptide modulates the vasoregulatory
effects of angiotensin II, Nat. Rev. Nephrol. (2015) (Epub ahead of print).
[14] M.M. Govender, A. Nadar, A subpressor dose of angiotensin II elevates blood
pressure in a normotensive rat model by oxidative stress, Physiol. Res. (2014)
(Epub ahead of print).
[15] M.J. Durand, J.H. Lombard, Low-dose angiotensin II infusion restores vascular
function in cerebral arteries of high salt-fed rats by increasing copper/zinc
superoxide dismutase expression, Am. J. Hypertens. 26 (6) (2013) 739–747.
[16] R.L. Soffer, Angiotensin-converting enzyme and the regulation of vasoactive
peptides, Annu. Rev. Biochem. 45 (1976) 73–94.
[17] L.T. Skeggs, J.R. Kahn, N.P. Shumway, The preparation and function of the
hypertensin-converting enzyme, Exp. Med. 103 (3) (1956) 295–299.
[18] S.H. Ferreira, Bradykinin potentiation factor (BPF) present in snake venom of
Bothrops jararaca, Br. J. Pharmacol. Chemother. 24 (1965) 163–169.
[19] D.W. Cushman, J. Pluscec, N.J. Williams, E.R. Weaver, E.F. Sabo, O. Kocy,
H.S. Cheung, M.A. Ondetti, Inhibition of angiotensin-converting enzyme by
analogs of peptides from Bothrops jararaca venom, Experientia 29 (8)
(1973) 1032–1035.
[20] M.A. Ondetti, B. Rubin, D.W. Cushman, Design of speciﬁc inhibitors of
angiotensin-converting enzyme: new class of orally active antihypertensive
agents, Science 196 (4288) (1977) 441–444.
J.D.A. Campeiro et al. / Biochemical Pharmacology 96 (2015) 202–215214[21] D.W. Cushman, M.A. Ondetti, Design of angiotensin converting enzyme
inhibitors, Nat. Med. 5 (10) (1999) 1110–1113.
[22] M.A. Ondetti, D.W. Cushman, Angiotensin-converting enzyme inhibitors:
biochemical properties and biological actions, CRC Crit. Rev. Biochem. 16 (4)
(1984) 381–411.
[23] M. Rocha e Silva, Bradykinin, Acta Physiol. Lat. Am. 12 (1962) 66–83.
[24] M. Hallberg, Neuropeptides: metabolism to bioactive fragments and the
pharmacology of their receptors, Med. Res. Rev. (2014), http://dx.doi.org/
10.1002/med.21323 (Epub ahead of print).
[25] G. Chandran, K.N. Sirajudeen, N.S. Yusoff, M. Swamy, M.S. Samarendra, Effect
of the antihypertensive drug enalapril on oxidative stress markers and
antioxidant enzymes in kidney of spontaneously hypertensive rat, Oxid. Med.
Cell Longev. 2014 (2014) 608512.
[26] R. Dong, X. Xu, G. Li, W. Feng, G. Zhao, J. Zhao, D.W. Wang, L. Tu, Bradykinin
inhibits oxidative stress-induced cardiomyocytes senescence via regulating
redox state, PLOS ONE 8 (10) (2013) e77034.
[27] N.G. Lumsden, R.S. Khambata, A.J. Hobbs, C-type natriuretic peptide (CNP):
cardiovascular roles and potential as a therapeutic target, Curr. Pharm. Des. 16
(37) (2010) 4080–4088.
[28] M. Dobrivojevic´, A. Sinpic´, B. Edemir, S. Kalweit, W.G. Forssmann, J.R. Hirsch,
Interaction between bradykinin and natriuretic peptides via RGS protein
activation in HEK-293 cells, Am. J. Physiol. Cell Physiol. 303 (12) (2012)
C1260–C1268.
[29] N. Murayama, M.A. Hayashi, H. Ohi, L.A. Ferreira, V.V. Hermann, H. Saito, Y.
Fujita, S. Higuchi, B.L. Fernandes, T. Yamane, A.C. de Camargo, Cloning and
sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven
bradykinin-potentiating peptides and a C-type natriuretic peptide, Proc. Natl.
Acad. Sci. U. S. A. 94 (4) (1997) 1189–1193.
[30] M.A. Hayashi, A.F. Murbach, D. Ianzer, F.C. Portaro, B.C. Prezoto, B.L. Fernandes,
P.F. Silveira, C.A. Silva, R.S. Pires, L.R. Britto, V. Dive, A.C. Camargo, The C-type
natriuretic peptide precursor of snake brain contains highly speciﬁc inhibitors
of the angiotensin-converting enzyme, J. Neurochem. 85 (4) (2003) 969–977.
[31] C. Lameu, V. Pontieri, J.R. Guerreiro, E.F. Oliveira, C.A. da Silva, J.M. Giglio, R.L.
Melo, R.R. Campos, A.C. de Camargo, H. Ulrich, Brain nitric oxide production
by a proline-rich decapeptide from Bothrops jararaca venom improves
baroreﬂex sensitivity of spontaneously hypertensive rats, Hypertens. Res. 33
(12) (2010) 1283–1288.
[32] C. Lameu, M.A. Hayashi, J.R. Guerreiro, E.F. Oliveira, I. Lebrun, V. Pontieri, K.L.
Morais, A.C. Camargo, H. Ulrich, The central nervous system as target for
antihypertensive actions of a proline-rich peptide from Bothrops jararaca
venom, Cytometry A 77 (3) (2010) 220–230.
[33] E.F. de Oliveira, J.R. Guerreiro, C.A. Silva, G.F. Benedetti, I. Lebrun, H. Ulrich, C.
Lameu, A.C. Camargo, Enhancement of the citrulline-nitric oxide cycle in
astroglioma cells by the proline-rich peptide-10c from Bothrops jararaca
venom, Brain Res. 1363 (2010) 11–19.
[34] C. Lameu, M. Neiva, M.A. Hayashi, Venom bradykinin-related peptides (BRPs)
and its multiple biological roles, in: G. Radis-Baptista (Ed.), An Integrated View
of the Molecular Recognition and Toxinology – From Analytical Procedures to
Biomedical Applications, InTech, 2013, http://dx.doi.org/10.5772/52872, ISBN:




[35] C.L. Gomes, K. Konno, I.M. Conceic¸a˜o, D. Ianzer, N. Yamanouye, B.C. Prezoto,
M.T. Assakura, G. Ra´dis-Baptista, T. Yamane, R.A. Santos, A.C. de Camargo, M.A.
Hayashi, Identiﬁcation of novel bradykinin-potentiating peptides (BPPs) in the
venom gland of a rattlesnake allowed the evaluation of the structure–function
relationship of BPPs, Biochem. Pharmacol. 74 (9) (2007) 1350–1360.
[36] D. Ianzer, R.A. Santos, G.M. Etelvino, C.H. Xavier, J. de Almeida Santos, E.P.
Mendes, L.T. Machado, B.C. Prezoto, V. Dive, A.C. de Camargo, Do the
cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-
independent mechanisms? New insights from proline-rich peptides of
Bothrops jararaca, J. Pharmacol. Exp. Ther. 322 (2) (2007) 795–805.
[37] G. Picolo, M. Hisada, A.B. Moura, M.F. Machado, J.M. Sciani, I.M. Conceic¸a˜o, R.L.
Melo, V. Oliveira, M.T. Lima-Landman, Y. Cury, K. Konno, M.A. Hayashi,
Bradykinin-related peptides in the venom of the solitary wasp Cyphononyx
fulvognathus, Biochem. Pharmacol. 79 (3) (2010) 478–486.
[38] M. Siqueira, A. Bandieri, M.S. Reis, O.A. Sant’anna, G. Biozzi, Selective breeding
of mice for antibody responsiveness to ﬂagellar and somatic antigens of
Salmonellae, Eur. J. Immunol. 6 (4) (1976) 241–249.
[39] A.R. Giles, Guidelines for the use of animals in biochemical research, Thromb.
Haemost. 58 (1987) 1078–1084.
[40] V. Ma¨de, S. Els-Heindl, A.G. Beck-Sickinger, Automated solid-phase peptide
synthesis to obtain therapeutic peptides, Beilstein J. Org. Chem. 10 (2014)
1197–1212.
[41] D. Ianzer, K. Konno, C.H. Xavier, R. Sto¨cklin, R.A. Santos, A.C. de Camargo, D.C.
Pimenta, Hemorphin and hemorphin-like peptides isolated from dog pancreas
and sheep brain are able to potentiate bradykinin activity in vivo, Peptides 27
(11) (2006) 2957–2966.
[42] S.F. Altschul, T.L. Madden, A.A. Scha¨ffer, J. Zhang, Z. Zhang, W. Miller, D.J.
Lipman, Gapped BLAST and PSI-BLAST: a new generation of protein database
search programs, Nucleic Acids Res. 25 (17) (1997) 3389–3402.
[43] A. Fiser, A. Sali, Modeller: generation and reﬁnement of homology-based
protein structure models, Methods Enzymol. 374 (2003) 461–491.
[44] G.N. Ramachandran, C. Ramakrishnan, V. Sasisekharan, Stereochemistry of
polypeptide chain conformations, J. Mol. Biol. 7 (1963) 95–99.[45] M. Wiederstein, M.J. Sippl, ProSA-web: interactive web service for the
recognition of errors in three-dimensional structures of proteins, Nucleic Acids
Res. 35 (Web Server issue) (2007) W407–W410.
[46] S. Sridharan, A. Nicholls, B. Honig, A new vertex algorithm to calculate solvent
accessible surface areas, Biophys. J. 61 (1992) A174.
[47] G. Neshich, R.C. Togawa, A.L. Mancini, P.R. Kuser, M.E. Yamagishi, G. Pappas Jr.,
W.V. Torres, T. Fonseca e Campos, L.L. Ferreira, F.M. Luna, A.G. Oliveira, R.T.
Miura, M.K. Inoue, L.G. Horita, D.F. de Souza, F. Dominiquini, A. Alvaro, C.S.
Lima, F.O. Ogawa, G.B. Gomes, J.F. Palandrani, G.F. dos Santos, E.M. de Freitas,
A.R. Mattiuz, I.C. Costa, C.L. de Almeida, S. Souza, C. Baudet, R.H. Higa, STING
Millennium: a Web based suite of programs for comprehensive and
simultaneous analysis of protein structure and sequence, Nucleic Acids Res. 31
(13) (2003) 3386–3392.
[48] G. Neshich, W. Rocchia, A.L. Mancini, M.E. Yamagishi, P.R. Kuser, R. Fileto, C.
Baudet, I.P. Pinto, A.J. Montagner, J.F. Palandrani, J.N. Krauchenco, R.C. Torres,
S. Souza, R.C. Togawa, R.H. Higa, JavaProtein Dossier: a novel web-based data
visualization tool for comprehensive analysis of protein structure, Nucleic
Acids Res. 32 (Web Server issue) (2004) W595–W601.
[49] W.L. Delano, The PyMOL Molecular Graphics System, Delano Scientiﬁc, San
Carlos, CA, USA, 2002, http://www.pymol.org.
[50] M.A. Larkin, G. Blackshields, N.P. Brown, R. Chenna, P.A. McGettigan, H.
McWilliam, F. Valentin, I.M. Wallace, A. Wilm, R. Lopez, J.D. Thompson, T.J.
Gibson, D.G. Higgins, Clustal W and Clustal X version 2.0, Bioinformatics 23
(21) (2007) 2947–2948.
[51] E. Gasteiger, C. Hoogland, A. Gattiker, S. Duvaud, M.R. Wilkins, R.D. Appel, A.
Bairoch, Protein identiﬁcation and analysis tools on the ExPASy Server, in: M.
John, Walker (Eds.), The Proteomics Protocols Handbook, Humana Press, 2005.
[52] E. Lolis, G.A. Petsko, Transition-state analogues in protein crystallography:
probes of the structural source of enzyme catalysis, Annu. Rev. Biochem. 59
(1990) 597–630.
[53] M. Abrink, J.A. Ortiz, C. Mark, C. Sanchez, C. Looman, L. Hellman, P. Chambon,
R. Losson, Conserved interaction between distinct Kru¨ppel-associated box
domains and the transcriptional intermediary factor 1 beta, Proc. Natl. Acad.
Sci. U. S. A. 98 (4) (2001) 1422–1426.
[54] D. Ianzer, K. Konno, R. Marques-Porto, F.C. Vieira Portaro, R. Sto¨cklin, A.C.
Martins de Camargo, D.C. Pimenta, Identiﬁcation of ﬁve new bradykinin
potentiating peptides (BPPs) from Bothrops jararaca crude venom by using
electrospray ionization tandem mass spectrometry after a two-step liquid
chromatography, Peptides 25 (7) (2004) 1085–1092.
[55] A.K. Tashima, A. Zelanis, E.S. Kitano, D. Ianzer, R.L. Melo, V. Rioli, S.S.
Sant’anna, A.C. Schenberg, A.C. Camargo, S.M. Serrano, Peptidomics of
three Bothrops snake venoms: insights into the molecular diversiﬁcation of
proteomes and peptidomes, Mol. Cell. Proteomics 11 (11) (2012) 1245–
1262.
[56] K.L. Morais, D. Ianzer, J.R. Miranda, R.L. Melo, J.R. Guerreiro, R.A. Santos, H.
Ulrich, C. Lameu, Proline rich-oligopeptides: diverse mechanisms for
antihypertensive action, Peptides 48 (2013) 124–133.
[57] D. Ianzer, C.H. Xavier, F.C. Fraga, R.Q. Lautner, J.R. Guerreiro, L.T. Machado, E.P.
Mendes, A.C. de Camargo, R.A. Santos, BPP-5a produces a potent and long-
lasting NO-dependent antihypertensive effect, Ther. Adv. Cardiovasc. Dis. 5 (6)
(2011) 281–295.
[58] R.E. Tunwell, C. Wickenden, B.M. Bertrand, V.I. Shevchenko, M.B. Walsh, P.D.
Allen, F.A. Lai, The human cardiac muscle ryanodine receptor-calcium release
channel: identiﬁcation, primary structure and topological analysis, Biochem. J.
318 (Pt 2) (1996) 477–487.
[59] Z.G. Wo, R.E. Oswald, A topological analysis of goldﬁsh kainate receptors
predicts three transmembrane segments, J. Biol. Chem. 270 (5) (1995) 2000–
2009.
[60] L.R. Tsuruta, M.A. Hayashi, K. Konno, D.V. Tambourgi, M.T. Assakura, A.C.
Camargo, O.A. Sant’anna, A natural carrier effect and the generation of
speciﬁc antibodies to biologically active peptides, Anal. Biochem. 353 (2)
(2006) 174–180.
[61] S.I. Liochev, I. Fridovich, Mechanism of the peroxidase activity of Cu, Zn
superoxide dismutase, Free Radic. Biol. Med. 48 (12) (2010) 1565–1569.
[62] T.D. Oury, J.D. Crapo, Z. Valnickova, J.J. Enghild, Human extracellular
superoxide dismutase is a tetramer composed of two disulphide-linked
dimers: a simpliﬁed, high-yield puriﬁcation of extracellular superoxide
dismutase, Biochem. J. 317 (Pt 1) (1996) 51–57.
[63] V. Bovenzi, M. Savard, J. Morin, C.M. Cuerrier, M. Grandbois, F. Gobeil Jr.,
Bradykinin protects against brain microvascular endothelial cell death induced
by pathophysiological stimuli, J. Cell. Physiol. 222 (1) (2010) 168–176.
[64] L.A. Dave, C.A. Montoya, S.M. Rutherfurd, P.J. Moughan, Gastrointestinal
endogenous proteins as a source of bioactive peptides – an in silico study,
PLOS ONE 9 (6) (2014) e98922.
[65] J.F. Paschoal, J. Yamaguchi, J.R. Miranda, G. Carretero, R.L. Melo, R.A. Santos,
C.H. Xavier, S. Schreier, A.C. Camargo, D. Ianzer, Insights into cardiovascular
effects of proline-rich oligopeptide (Bj-PRO-10c) revealed by structure–activity
analyses: dissociation of antihypertensive and bradycardic effects, Aminoacids
46 (2) (2014) 401–413.
[66] A. Ahmad, U. Singhal, M.M. Hossain, N. Islam, I. Rizvi, The role of the
endogenous antioxidant enzymes and malondialdehyde in essential
hypertension, J. Clin. Diagn. Res. 7 (6) (2013) 987–990.
[67] T. Gaillot, A. Beuche´e, S. Jaillard, L. Storme, A.M. Nuyt, F. Carre´, P. Pladys,
Inﬂuence of sympathetic tone on heart rate during vagal stimulation and
nitroprusside induced hypotension in ovine fetus, Auton. Neurosci. 123 (1–2)
(2005) 19–25.
J.D.A. Campeiro et al. / Biochemical Pharmacology 96 (2015) 202–215 215[68] G.C. Brailoiu, E. Deliu, J.E. Rabinowitz, D.G. Tilley, W.J. Koch, E. Brailoiu,
Urotensin II promotes vagal-mediated bradycardia by activating cardiac-
projecting parasympathetic neurons of nucleus ambiguus, J. Neurochem. 129
(4) (2014) 628–636.
[69] R. Wan, L.A. Weigand, R. Bateman, K. Grifﬁoen, D. Mendelowitz, M.P. Mattson,
Evidence that BDNF regulates heart rate by a mechanism involving increased
brainstem parasympathetic neuron excitability, J. Neurochem. 129 (4) (2014)
573–580.[70] K.J. Osterziel, R. Dietz, Improvement of vagal tone by ACE inhibition: a
mechanism of cardioprotection in patients with mild-to-moderate heart
failure, J. Cardiovasc. Pharmacol. 27 (Suppl. 2) (1996) S25–S30.
[71] A. Vitali, Proline-rich peptides: multifunctional bioactive molecules as new
potential therapeutic drugs, Curr. Protein Pept. Sci. 16 (2) (2015) 147–162.
[72] H. Jiang, Z. Wei, R.J. Nachman, M.E. Adams, Y. Park, Functional phylogenetics
reveals contributions of pleiotropic peptide action to ligand–receptor
coevolution, Sci. Rep. 4 (2014) 6800.
